Outset Medical, Inc. (OM)
NASDAQ: OM · IEX Real-Time Price · USD
2.340
0.00 (0.00%)
Apr 23, 2024, 9:45 AM EDT - Market open
Outset Medical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Outset Medical stock have an average target of 5.30, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 126.50% from the current stock price of 2.34.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Outset Medical stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +156.41% | Apr 8, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $14 → $6 | Buy → Hold | Downgrades | $14 → $6 | +156.41% | Jan 12, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $5.5 | Hold | Maintains | $5 → $5.5 | +135.04% | Dec 4, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $19 → $5 | Hold | Maintains | $19 → $5 | +113.68% | Nov 14, 2023 |
| RBC Capital | RBC Capital | Buy Maintains $29 → $17 | Buy | Maintains | $29 → $17 | +626.50% | Oct 13, 2023 |
Financial Forecast
Revenue This Year
152.87M
from 130.38M
Increased by 17.25%
Revenue Next Year
179.14M
from 152.87M
Increased by 17.18%
EPS This Year
-2.12
from -3.48
EPS Next Year
-1.85
from -2.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 157.6M | 188.0M | 224.0M | 261.6M | 306.1M |
| Avg | 152.9M | 179.1M | 214.2M | 255.4M | 300.3M |
| Low | 142.8M | 162.4M | 200.9M | 242.0M | 285.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20.9% | 22.9% | 25.0% | 22.1% | 19.8% |
| Avg | 17.3% | 17.2% | 19.6% | 19.2% | 17.5% |
| Low | 9.5% | 6.2% | 12.1% | 13.0% | 11.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.05 | -1.73 | -1.23 | -0.59 | -0.50 |
| Avg | -2.12 | -1.85 | -1.42 | -0.85 | -0.49 |
| Low | -2.14 | -1.95 | -1.52 | -1.08 | -0.47 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.